Kairos Pharma, Ltd. (KAPA)
| Market Cap | 8.26M -49.6% |
| Revenue (ttm) | n/a |
| Net Income | -5.84M |
| EPS | -0.30 |
| Shares Out | 21.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 624,344 |
| Open | 0.3957 |
| Previous Close | 0.3900 |
| Day's Range | 0.3700 - 0.4056 |
| 52-Week Range | 0.2695 - 2.1100 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 7.00 (+1,713.47%) |
| Earnings Date | Aug 12, 2026 |
About KAPA
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company’s pro... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for KAPA stock is "Buy." The 12-month stock price target is $7.0, which is an increase of 1,713.47% from the latest price.
News
Kairos Pharma announces collaboration with Bayer to enhance XOFIGO
Kairos Pharma (KAPA) announced a strategic collaboration with Bayer (BAYRY) to evaluate Kairos Pharma’s lead antibody ENV-105, a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer...
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
LOS ANGELES--(BUSINESS WIRE)---- $KAPA #Bayer--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a str...
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining e...
Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105
Kairos Pharma (KAPA) announced interim safety data from its ongoing Phase 1 clinical trial evaluating ENV-105 in combination with osimertinib in patients with advanced EGFR-mutated non-small cell lung...
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced compelling interim safety data...
Kairos Pharma Transcript: AGM 2026
The meeting covered director elections, auditor ratification, a reverse stock split, executive compensation, and equity plan amendments. All proposals were approved by stockholders, with final results to be filed with the SEC. Stockholders were invited to submit questions.
Kapa Gold Announces the Results of Its 2026 Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 19, 2026) - KAPA GOLD INC. (TSXV: KAPA) ("Kapa" or the "Company") is pleased to announce the results of its annual meeting of shareholders held virt...
Kairos Pharma issues letter from CEO that recaps year, details plans for 2026
Kairos Pharma (KAPA) provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from CEO John Yu, M.D.: “As…
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides a mid-year update for 2026 and a ...
Kairos Pharma Proxy statement: Proxy filing
Kairos Pharma filed a proxy statement on May 26, 2026, providing details for shareholder voting and corporate governance matters.
Kairos Pharma Proxy statement: Proxy filing
Kairos Pharma filed a proxy statement on May 22, 2026, providing details for shareholder voting and corporate governance matters.
Kairos Pharma Transcript: 16th Annual LD Micro Invitational Conference
Multiple clinical programs are advancing, including ENV-105 for drug-resistant cancers and KROS-741 for EGFR therapy resistance, supported by strong non-dilutive funding and strategic partnerships. Key clinical and collaboration milestones are expected in 2026, with a focus on rapid trial execution through academic consortia.
Kairos Pharma Slides: Investor presentation
Kairos Pharma has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner ...
Kairos Pharma Quarterly report: Q1 2026
Kairos Pharma has published its Q1 2026 quarterly earnings report on May 13, 2026.
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
Los Angeles, California--(Newsfile Corp. - May 13, 2026) - Kairos Pharma, Ltd. (NYSE American: KAPA) announced today that it will be participating in the 16th Annual LD Micro Invitational at the Luxe ...
Kairos Pharma Proxy statement: Proxy filing
Kairos Pharma filed a proxy statement on May 11, 2026, providing details for shareholder voting and corporate governance matters.
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that its Annual Meeting of Shar...
Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner ...
Kairos Pharma Annual report: Q4 2025
Kairos Pharma has published its Q4 2025 annual report on March 31, 2026.
Kairos Pharma to acquire CL-273 from Celyn Therapeutics
Kairos Pharma (KAPA) announces that it has entered into binding terms to acquire CL-273 from Celyn Therapeutics, a company backed by OrbiMed and Torrey Pines Investment. John Yu, M.D., Kairos…
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it has entered into ...
Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn
Kairos Pharma (KAPA) announced the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide…
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term she...
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it will participate i...